Saturday 17 October 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
32.38
1.27
−3.77%
Follow KRSA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 2 | — | — | — |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (1.79) | (2.86) | (3.54) | (20.72) | — | (33.00) | (36.29) |
P/S ratio |
— | — | — | 0.00 | 40.53 | 17.09 | 35.13 | — | 5.11 | 1.95 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (1.93) | (5.87) | (8.59) | (49.57) | — | (78.40) | (78.78) |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
P/Operating CF |
— | — | — | (3.36) | (6.63) | (7.80) | (4.14) | — | 22.53 | (2.56) |
Beneish M-Score |
— | — | — | — | (4.16) | (3.95) | 11.62 | — | — | (1.95) |
P/B ratio |
— | — | — | 0.76 | 1.56 | 1.40 | 2.79 | — | 0.92 | 0.44 |
Price to Tangible BV |
— | — | — | 0.76 | 1.56 | 1.40 | 2.79 | — | 0.92 | 0.44 |
EV/Sales |
— | — | — | 0.00 | 16.84 | 3.40 | 18.99 | — | 3.08 | 0.39 |
EV/EBITDA |
— | — | — | 0.17 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | 0.20 | (0.53) | (0.37) | (0.39) | — | (1.13) | (0.24) |
EV/FCF |
— | — | — | 0.19 | (0.53) | (0.38) | (0.40) | — | (1.70) | (0.43) |
Quick Ratio |
0.00 | 0.00 | 0.00 | 5.28 | 3.22 | 4.88 | 1.77 | 3.63 | 5.22 | 4.71 |
Current Ratio |
0.03 | 0.09 | 0.05 | 5.55 | 3.45 | 5.00 | 1.94 | 3.85 | 5.83 | 5.15 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.78 | 0.69 | 0.99 | 0.72 | 0.58 | 0.89 | 0.65 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.05 | 0.02 | 0.05 | 0.01 | 0.00 | 0.17 | 0.21 |
Operating CF/Net income |
0.78 | 0.86 | 0.85 | 0.83 | 0.93 | 0.71 | 0.92 | 4.04 | 1.42 | 0.94 |
Capex/Depreciation |
0.00 | (0.80) | (2.25) | (2.49) | 0.01 | 3.09 | 0.00 | — | — | — |
| 829.25% | 1,225.50% | 1,212.41% | (281.86%) | (98.97%) | (95.87%) | (150.19%) | (48.42%) | (30.36%) | (39.34%) | |
| (1,360.17%) | (2,010.10%) | (1,790.88%) | (126.89%) | (51.55%) | (59.12%) | (113.88%) | (33.47%) | (26.64%) | (36.07%) | |
ROIC |
0.00% | 0.00% | 0.00% | (2,757.52%) | (996.29%) | 0.00% | 0.00% | (217.77%) | (40.36%) | (53.18%) |
Return on Tangible Assets |
940.01% | 1,086.18% | 1,100.78% | (130.08%) | (160.70%) | (116.23%) | (612.79%) | (88.63%) | (87.34%) | (94.46%) |
Average Days of Receivables |
— | — | — | 119.37 | 20.19 | 9.26 | 117.98 | — | 101.47 | 175.99 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,110.94% | 2,457.06% | 954.74% | 2,013.13% | 0.00% | 14.30% | 46.24% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 763.35% | 1,255.05% | 523.08% | 4,329.29% | 0.00% | 267.10% | 293.54% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 435.57% | 652.96% | 243.81% | 2,105.05% | 0.00% | 31.25% | 21.26% |
Graham Net Nets |
— | — | — | 0.17 | 0.03 | 0.66 | 0.25 | — | 0.43 | 0.92 |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (165.22%) | (83.96%) | (78.07%) | (150.70%) | — | (37.88%) | (91.31%) |
Free Cash Flow Yield |
— | — | — | (146.25%) | (77.89%) | (52.06%) | (134.43%) | — | (35.46%) | (45.95%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 23.04 | 10.57 | 14.09 | 0.96 | 0.00 | 5.56 | 4.56 |
Operating CF per Share |
(1.82) | (2.96) | (498.48) | (522.57) | (333.75) | (130.56) | (130.79) | (63.59) | (12.04) | (7.29) |
Capex per Share |
0.00 | (0.05) | (17.58) | (34.33) | 0.08 | 5.21 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.82) | (3.02) | (516.06) | (556.90) | (333.66) | (125.35) | (130.79) | (63.59) | (12.04) | (7.29) |
Cash per Share |
0.00 | 0.00 | 0.00 | 485.15 | 250.44 | 192.92 | 43.10 | 22.66 | 8.98 | 7.13 |
Shareholders Equity per Share |
(0.25) | (0.31) | (53.40) | 499.64 | 273.91 | 172.49 | 33.66 | 33.79 | 24.60 | 19.98 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.25) | (0.31) | (53.40) | 499.64 | 273.91 | 172.49 | 33.66 | 33.79 | 24.60 | 19.98 |
Free Cash Flow |
(49.87) | (82.62) | (100.94) | (108.93) | (72.47) | (35.06) | (40.61) | (21.24) | (4.33) | (3.31) |
Working Capital |
(10.36) | (12.78) | (16.97) | 82.95 | 41.55 | 44.37 | 7.19 | 5.94 | 3.50 | 3.74 |
Capital Expenditures |
(1.44) | (1.40) | (3.44) | (6.71) | 0.02 | 1.46 | — | — | — | — |
Net Current Asset Value |
(10.36) | (12.78) | (16.97) | 12.45 | 2.62 | 44.37 | 7.19 | 5.94 | 3.50 | 3.74 |
EV/EBIT |
— | — | — | 0.16 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 1.49 | (0.01) | (0.37) | 0.00 | — | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.60 | 0.42 | 0.24 | 0.23 | 0.33 | 7.26 | 0.00 | — | — | — |
Cash ROIC |
737.67% | 964.42% | 966.40% | (56.55%) | (63.63%) | (34.30%) | (170.39%) | (112.65%) | (35.86%) | (26.89%) |
Accounts Receivable Turnover |
— | — | — | 5.63 | 2.87 | 34.73 | 3.03 | — | 6.14 | 2.67 |
Accounts Payable Turnover |
1.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
236.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 0.80 | 0.80 | 0.11 | 0.10 | — | 0.33 | 0.78 |
Average Payables |
1.61 | 1.61 | 2.29 | 3.05 | 2.37 | 1.63 | 2.40 | 2.08 | 0.79 | 0.45 |
Average Assets |
4.67 | 4.67 | 6.44 | 96.94 | 150.93 | 87.35 | 38.71 | 15.73 | 11.47 | 9.78 |
Average Common Equity |
(7.66) | (7.66) | (9.51) | 43.64 | 78.61 | 53.87 | 29.35 | 10.87 | 10.07 | 8.97 |
Columns are period end dates